Serena Ruggieri, Antonio Ianniello, Massimiliano Copetti, Marta Altieri, Diego Centonze, Antonio Cortese, Laura De Giglio, Roberta Fantozzi, Carla Tortorella, Claudio Gasperini, Luigi Me Grimaldi, Doriana Landi, Girolama A Marfia, Massimiliano Mirabella, Riccardo Nistri, Viviana Nociti, Oscar Oddo, Silvia Romano, Giuseppe Salemi, Marco Salvetti, Carlo Pozzilli, Maria Petracca
Despite its widespread use in clinical practice, the effectiveness of natalizumab extended interval dosing (EID) adopted from treatment start across different treatment intervals and individual modifiers (body mass index - BMI) is still under-investigated. Here, seven-hundred and forty-five multiple sclerosis (MS) patients, exposed to natalizumab for 3.30 ± 1.34 years, were retrospectively enrolled in an observational multicenter study. After stratifying patients in EID or standard interval dosing (SID), we assessed differences in time to relapse, MRI activity and Expanded Disability Status Scale (EDSS) progression...
February 26, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics